Market Newsdesk

• Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) 
  set-up
  data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an
  
  immediate
  
  
  average reduction of 13.2 mmHg
  
  in office systolic blood pressure (“oSBP”)
• 
  97%
  
  
  of patients experienced an immediate blood pressure reduction
  
  of >5 mmHg reduction in oSBP prior to randomization
• A
  VIM Therapy demonstrated the potential to deliver
  
  immediate, substantial, and sustained reductions
  
  in blood pressure, with evidence of improved diastolic function and reverse cardiac remodeling
• The BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboration with Medtronic (NYSE: MDT), targets a similar patient population as MODERATO II using a similar approach to blood pressure assessment and AVIM Therapy activation

NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two AVIM Therapy presentations at the Heart Rhythm Society (HRS) 2026 Annual Meeting.

HRS 2026 Presentations and Data Highlights


Atrioventricular Interval Modulation (AVIM) Therapy as a Treatment for Hypertensive Heart Disease (Saturday, April 25, 10:06-10:18am, Room S102 McCormick Place)

Prof.
Karl-Heinz Kuck, M.D., Medical Director, LANS Cardio Hamburg will present new data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial which demonstrate AVIM Therapy’s potential to deliver immediate, substantial, and sustained blood pressure reduction without reliance on additional medications or patient adherence. Key findings include:

• 
  An Immediate and Substantial oSBP Reduction
  
  : Upon activation, AVIM Therapy demonstrated a mean reduction in oSBP of 13.2 mmHg.
• 
  A High Responder Rate
  
  : 97% of patients achieved a 5 mmHg or greater reduction in oSBP.
• 
  High Rates of Sustained Blood Pressure Control:
  At 6 months, mean ambulatory systolic blood pressure (“aSBP”) was 125.2 mmHg, with 89% of patients achieving aSBP <140 mmHg, the current oSBP treatment goal according to European Society of Cardiology guidelines, and 58% of patients achieving aSBP <130 mmHg, the more stringent U.S. oSBP treatment goal according to American Heart Association and American College of Cardiology guidelines.
• 
  Durable Long-Term Effect
  
  : Sustained reductions in aSBP were observed through 3.6 years of follow-up in a sub-cohort of patients.

Prof. Kuck
, who also served as Principal Investigator for the MODERATO II pilot trial, commented, “The observed response rate and mean blood pressure reduction in the MODERATO II trial provide a clear and consistent baseline signal of AVIM Therapy’s effect. The magnitude of ambulatory blood pressure reduction brought the majority of patients well within contemporary guideline-recommended targets for optimal blood pressure control. We look forward to further results from the BACKBEAT Global Pivotal Trial as AVIM Therapy, in combination with a modest medical regimen, may offer a differentiated path to sustained blood pressure control in this older, higher-risk patient population.”

Pressure-Volume Analysis Demonstrates Hemodynamic Effects of Atrioventricular Interval Modulation (AVIM) Therapy in Hypertension

(Friday, April 24, 10:00am-12:00pm, Abstract Pavilion – Exhibit Hall, McCormick Place)

Prof. Milan Chovanec, M.D., Na Hamolce Hospital will present results from a clinical pressure-volume loop trial of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of anti-hypertensive medication. These data, which were published in JACC: Clinical Electrophysiology, demonstrate the favorable impact of AVIM Therapy compared to standard pacing on systolic blood pressure (“SBP”) and overall cardiac function when delivered using both conduction system pacing (“CSP”) and standard right ventricular (“RV”) pacing lead locations.

AVIM Therapy acutely reduced SBP by decreasing cardiac preload and effective arterial elastance (afterload) independent of lead location without affecting left ventricular contractility. When compared to AV pacing, AVIM Therapy drove statistically significant (p<0.05) reductions in:

• Systolic blood pressure, end diastolic volume, end diastolic pressure, and end systolic volume using both CSP and RV pacing lead locations
• Stroke work without significantly reducing stroke volume
• Total peripheral resistance (measured by Ea) and no change in contractility

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue^® Sirolimus AngioInfusion™ Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

About AVIM Therapy

AVIM Therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot trial, showed that patients treated with AVIM Therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal trial will evaluate the safety and efficacy of AVIM Therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted Breakthrough Device Designation by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the initiation, enrollment, timing, implementation and design of the Company’s ongoing pivotal trials, realizing the clinical and commercial value of AVIM Therapy and Virtue SAB, the potential safety and efficacy of the Company’s product candidates, including the ability of AVIM Therapy to deliver sustained reductions in blood pressure and cardiac hemodynamic benefits, and the ability of the Company’s partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 12, 2026.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Investor Contact:

Silas Newcomb
Orchestra BioMed
[email protected]

Media Contact:

Kelsey Kirk
Orchestra BioMed
[email protected]

VIVO System to be featured in educational sessions at HRS

Accepted manuscripts for LockeT and VIVO are now published and available online

FORT MILL, S.C., April 23, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 47^th annual Heart Rhythm Society (HRS) meeting. The HRS meeting will take place from April 24^th to the 27^th in Chicago, Illinois.

HRS announced that the 47^th conference will bring together more than 10,000 professionals worldwide for a global exchange of science and innovation advancing electrophysiology (EP). Designed by and for heart rhythm professionals, the meeting features almost 2,000 sessions, posters, roundtables, and hands-on experiences highlighting the latest breakthroughs in arrhythmia care.

Heart Rhythm 2026 received the highest number of abstract submissions in its history, including a fourfold increase in late-breaking science over the past decade, a testament to the rapid growth in the EP field. The meeting continues to serve as a premier forum where practice-changing research is unveiled, sparking the most important conversations and fueling unprecedented scientific advancement across the field.

New Data Presented at the Heart Rhythm Society Meeting

One abstract on Catheter Precision’s VIVO system was accepted and the data will be presented in a poster format on Friday, April 24. In addition, Professor Tarvinder Dhanjal was invited to speak during a core session on the VIVO system on Saturday, April 25.

• Friday April 24, 2026 – Ventricular arrythmia localization using implanted cardioverter defibrillator intracardiac electrogram recordings
  • This study is novel and the first to demonstrate feasibility of using intra-cardiac electrodes rather than a surface 12-lead ECG to accurately identify ventricular tachycardia (VT)
  • While more research is being conducted, this feasibility indicated VIVO may provide patients with safer VT diagnosis and allow treatment for a currently difficult to treat patient population
• Saturday, April 25, 2026 – Leveraging recorded CIED and EKG data in creating integrated models for accurate localization of arrythmias with real time 3D mapping
  • This session will highlight VIVO’s benefits for improved workflow and accurate localization to improve the identification of areas of interest for ventricular ablation procedures

New Publications for Both LockeT and VIVO are Available Online

Recently, Catheter Precision announced the acceptance of two publications, one for LockeT and one for VIVO, in leading electrophysiology journals.

New data demonstrating the benefits of LockeT in large-bore electrophysiology procedures was accepted by the Journal of Cardiovascular Electrophysiology. This study, found here, included 139 patients and concluded that LockeT demonstrated high procedural success, rapid hemostasis, early ambulation, and low complication rates for venous closure following EP procedures requiring large-bore venous access (LBVA). These findings support LockeT as a feasible and effective venous closure strategy in contemporary EP practice.

A new VIVO study was accepted by leading European journal, EP Europace. This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. The study concluded that VIVO can accurately predict the arrhythmogenic substrate for scar-dependent VT and incorporation of VIVO mapping to conventional VT ablation workflows improves procedural efficiency.

David Jenkins, CEO of Catheter Precision, said, “Having an abstract accepted at any conference is an accomplishment. Somewhere around 50% of abstracts are accepted and knowing that this is the largest submission of ground-breaking data ever at HRS means that the research and products resonate with the abstract committee. Further, to have one of our VIVO users be asked to present a session highlights the excitement around not just the product, but the benefits that VIVO brings to patients, hospitals and physicians. We anticipate HRS 2026 to be a symposium where we not only demonstrate our products to new and existing customers, but where we can share new and exciting research, like the new peer reviewed publications, that validate our products to the EP community.”

About LockeT

Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.

About VIVO

Catheter Precision’s VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding our anticipation HRS 2026 will be a symposium where we not only demonstrate our products to new and existing customers, but where we can share new and exciting research, like the new peer-reviewed publications, that validate our products to the EP community. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

At the Company

David Jenkins
973-691-2000
[email protected]

# # #

Issued on behalf of VisionWave Holdings, Inc., Starfighters Space, Inc., Avaí Bio, Inc., Lake Victoria Gold Ltd., and QSE – Quantum Secure Encryption Corp.

Five small-cap companies operating in very different sectors share one trait that tends to precede re-ratings: near-term catalysts that have already started to land.

Companies Mentioned in this Article: VisionWave Holdings, Inc. (NASDAQ: VWAV), Starfighters Space, Inc. (NYSE American: FJET), Avaí Bio, Inc. (OTCQB: AVAI), Lake Victoria Gold Ltd. (TSXV: LVG) (OTCQB: LVGLF) (FSE: E1K), QSE – Quantum Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN80)

Key Takeaways:

• VisionWave Holdings (NASDAQ: VWAV) closed a $20 million senior loan in late February, completed a $60 million–valued AI video intelligence IP acquisition on April 10, and announced a term sheet on April 21 to acquire up to 51% of Foresight Autonomous Holdings (NASDAQ: FRSX) — stacking three transformative catalysts inside roughly eight weeks.
• Starfighters Space (NYSE American: FJET) rang the NYSE Opening Bell on February 20, expanded its Blackstar Orbital hypersonic flight-test program, added a microgravity partnership with Mu-GTech, and on April 22 joined an NSF-backed space manufacturing research consortium at Kennedy Space Center.
• Avaí Bio (OTCQB: AVAI) — formerly Avant Technologies — completed its rebrand on February 11, kicked off GMP production of a Master Cell Bank for its α-Klotho anti-aging therapy on March 3, and will present the latest data alongside the scientist who discovered the Klotho gene at the Second Annual Klotho Conference in September.
• Lake Victoria Gold (TSXV: LVG) confirmed up to ~97% gold recoveries at its fully permitted Imwelo project, advanced Tembo toward near-term production, and on April 1 agreed to terms for up to ~US$25 million in gold loan financing from Monetary Metals plus a fully committed $3 million convertible debenture — funding the transition from explorer to cash-flow generator.
• QSE – Quantum Secure Encryption (CSE: QSE) launched QPA v2, its enterprise post-quantum cryptographic migration platform, on March 31 — arriving exactly as Canada’s federal PQC migration-plan deadline hits and as the company expanded to 13 countries, landed its first municipal government pilot, and headed onto the global cybersecurity conference circuit.

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — World Street Intelligence News Commentary — Small-cap investing is an exercise in timing. A company can have the right story, the right sector, and the right team for quarters before the market rewards any of it. What changes the equation is catalysts — specific, dated, verifiable events that force a re-reading of the story. The five companies below are all trading under the radar of mainstream coverage, and all five have stacked multiple catalysts into the first four months of 2026. The common thread is not a sector. It is momentum — the kind that typically shows up in press releases before it shows up in share price.

VisionWave Holdings (NASDAQ: VWAV) — Three Transformative Deals in Eight Weeks

VisionWave Holdings, Inc. (NASDAQ: VWAV) has spent the first quarter of 2026 assembling what management describes as an integrated multi-domain intelligence platform — one that spans RF-based sensing, AI video intelligence, autonomous systems, and computational acceleration. The pace has been remarkable for a company of its size.

On February 27, 2026, VisionWave closed and funded a $20 million senior loan financing, giving the company working capital and a clean balance sheet heading into a series of strategic transactions. A month later, on March 30, management issued a comprehensive corporate update outlining the Company’s strategy to build out a platform covering autonomous aerial and ground systems, subsurface sensing and energy intelligence, and AI infrastructure — including the formation of an Israeli subsidiary and an exploratory Liberia offshore initiative.

Then came the acquisitions. On April 10, 2026, VisionWave completed the acquisition of the intellectual property assets underlying the xClibre™ AI video intelligence platform, an IP portfolio independently valued at approximately $60 million by BDO Consulting Group. The acquisition fills what management has called a critical capability gap — until xClibre, VisionWave’s platforms relied primarily on RF-based detection. Adding visual perception creates a multi-sensor defense stack that is considerably more attractive to defense, homeland security, and critical infrastructure customers.

Ten days later, on April 21, VisionWave announced a signed non-binding term sheet to acquire up to 51% of Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX), an innovator in 3D perception systems, in exchange for $17.5 million in VisionWave equity. The transaction is structured in two stages: 45% at initial closing, with an additional 6% contingent on the commencement of a qualifying pilot project in the defense or security sector. Taken together, the xClibre and Foresight transactions are designed to accelerate VisionWave’s push into air, land, and sea applications with a differentiated sensing-and-perception stack. That is a lot of strategic real estate for a microcap to cover in two months, and the market is still catching up to it.

Learn more about VisionWave Holdings at

USANewsGroup.com/vwave-profile

Starfighters Space (NYSE American: FJET) — Commercial Supersonic Platform Building Cadence

Starfighters Space, Inc. (NYSE American: FJET) operates what it describes as the world’s only commercial fleet capable of flying payloads at sustained MACH 2+ — modified F-104 supersonic aircraft operated out of NASA’s Kennedy Space Center. The Company’s value proposition sits at the intersection of three trends that are all accelerating simultaneously: commercial space, hypersonic testing, and next-generation air-launch.

The catalysts have been coming steadily. On February 20, 2026, Starfighters’ executive leadership rang the Opening Bell at the New York Stock Exchange — a symbolic but meaningful milestone that followed the Company’s successful completion of supersonic flight testing in support of GE Aerospace’s ATLAS propulsion program and the completion of wind tunnel validation for the Company’s STARLAUNCH 1 air-launch vehicle, including confirmed clean separation across subsonic and supersonic regimes. On February 26, the Company announced an expansion of its operational presence at the Midland International Air & Space Port in Texas, relocating aircraft, engines, and support equipment to support an anticipated increase in mission cadence — Midland gives Starfighters access to nine additional locations including spaceports, Air Force bases, and test ranges across the U.S. Southwest.

March brought additional technical partnerships. On March 10, Starfighters announced a partnership with Mu-G Technologies, LLC to pursue microgravity flight missions for NASA, academic institutions, and commercial research customers. On March 30, Starfighters and Blackstar Orbital announced a strategic partnership focused on flight testing next-generation reusable hypersonic space systems, including Blackstar’s SpaceDrone platform — an agreement that was meaningfully broadened on April 15 during the 41st Space Symposium to cover integration planning, wind tunnel testing, telemetry and data requirements, and drop-test and flight-test readiness.

Most recently, on April 22, 2026, Starfighters announced it had joined the Center for Science, Technology, and Advanced Research in Space (C-STARS), a proposed National Science Foundation Industry–University Cooperative Research Center based at the University of Florida. C-STARS is focused on advancing space manufacturing — biotechnology, advanced materials, electronics, and in-space manufacturing — and Starfighters has committed $50,000 annually to support the initiative. The partnership plugs Starfighters into a federally backed research ecosystem at exactly the moment when space manufacturing is transitioning from research concept to commercial opportunity.

Learn more about Starfighters Space at

USANewsGroup.com/fjet-profile

Avaí Bio (OTCQB: AVAI) — Anti-Aging Moves from Concept to Master Cell Bank

Avaí Bio, Inc. (OTCQB: AVAI) is a microcap biotechnology company working at the intersection of three of the most closely watched areas in medicine: cell-based therapies, diabetes, and the biology of aging itself. On February 11, 2026, the company completed its rebrand from Avant Technologies to Avaí Bio — a corporate identity change that aligns with its sharpened focus on genetically modified cellular platforms protected by proprietary encapsulation technology.

The company’s lead anti-aging program, Klothonova, is a joint venture with Austrianova — a Singapore-based global biotechnology firm specializing in cell encapsulation with more than 50 peer-reviewed publications to its name. Klothonova was established in September 2025 as a Nevada-based entity equally owned by Avaí Bio and Austrianova’s affiliate SG Austria Pte. Ltd. The scientific premise is straightforward and consequential: α-Klotho is a protein whose circulating levels decline sharply with age and whose supplementation has been linked in published research to improvements in cardiovascular, kidney, and cognitive function. Klothonova is working to use Austrianova’s Cell-in-a-Box® encapsulation platform to protect genetically modified cells that overexpress α-Klotho — in effect, creating a sustainable, cell-based approach to restoring the “longevity protein” in patients.

On March 3, 2026, the two partners announced they had initiated production of a Master Cell Bank (MCB) of the genetically modified α-Klotho-overexpressing cells, following the successful completion of all preparatory activities in February. An MCB is a GMP-compliant, fully characterized collection of vials that forms the foundation for clinical-grade cell therapy manufacturing. Establishing the MCB is the step that moves a program from laboratory concept toward scalable production — a meaningful de-risking event for any cell therapy program.

On April 7, Avaí Bio announced that Klothonova will present its latest α-Klotho production data at the Second Annual Klotho Conference in September, alongside Dr. Makoto Kuro-o — the physician-scientist widely credited with discovering the Klotho gene. For a microcap program, a podium at that conference next to the gene’s discoverer is the kind of credibility signal that is difficult to manufacture. Avaí Bio’s second program, Insulinova, targets diabetes using the same encapsulated-cell approach — giving the company two shots at a clinical thesis that connects directly into two of the largest therapeutic markets on the planet.

Learn more about Avaí Bio at

USANewsGroup.com/avai-profile

Lake Victoria Gold (TSXV: LVG) — Financed, Permitted, and Moving Toward First Pour

Lake Victoria Gold Ltd. (TSXV: LVG) (OTCQB: LVGLF) (FSE: E1K) has spent the first four months of 2026 doing something that relatively few junior gold companies have managed this cycle: completing the technical, permitting, and financing steps required to turn a fully permitted deposit into a producing mine.

The Company’s fully permitted Imwelo Gold Project — located west of AngloGold Ashanti’s Geita Gold Mine in northern Tanzania’s Lake Victoria Goldfield — has been the focus of intensive technical work. On January 26, the Company announced the completion of field data collection for geotechnical studies and specific gravity measurements supporting final open-pit design at Area C, the initial mining area. On February 5, Lake Victoria Gold announced the completion of drilling and receipt of all analytical results from the Area C drill program, confirming down-dip continuity of mineralization below the current pit design and defining new mineralized extensions to the west and east. On March 18, the Company reported metallurgical testwork demonstrating gold recoveries of up to approximately 96–97% using conventional gravity concentration and cyanide leaching, confirming that Imwelo’s mineralization is largely free-milling and consistent with earlier test programs from 2013, 2014, and 2017.

The Tembo Project — Lake Victoria’s second asset, located directly adjacent to Barrick Gold’s Bulyanhulu mine — is advancing on a parallel track. On March 25, Lake Victoria Gold announced that its Tanzanian subsidiary had received formal notice from the Tanzanian Mining Commission initiating the process to incorporate the Government of Tanzania’s 16% non-dilutable free carried interest in the Tembo mining licences, while the Company continues to advance negotiations toward a binding toll-milling agreement with Nyati Resources at the neighbouring 500-tpd plant to enable near-term production from Tembo ore.

The capstone catalyst came on April 1, 2026: Lake Victoria Gold announced it had agreed to terms for a gold loan facility of up to 6,000 ounces of gold (approximately US$25 million) with Monetary Metals & Co., along with a fully committed $3 million non-brokered convertible debenture financing. The Monetary Metals facility is denominated in gold ounces (carrying a 15% annual interest rate with multi-year amortization) and is structured as non-dilutive project-level financing for Imwelo. This is the piece of the story that typically drives a re-rating for a gold developer — the financing that bridges a permitted, engineered, and metallurgically de-risked project into production. Management has laid out a 2026 roadmap that contemplates Imwelo production start, commissioning of the 500-tpd Nyati plant supplied with ore from Tembo, and continuing exploration payments from Barrick’s $9 million exploration program on transferred license areas.

Learn more about Lake Victoria Gold at

USANewsGroup.com/lvg-profile

QSE – Quantum Secure Encryption (CSE: QSE) — Product Launch Into a Regulatory Deadline

QSE – Quantum Secure Encryption Corp. (CSE: QSE) (OTCQB: QSEGF) (FSE: VN80) is a Canadian technology company building post-quantum cryptographic infrastructure — and it has timed a product launch directly into one of the most structured regulatory migrations in the history of enterprise cybersecurity.

The backdrop is significant. In August 2024, the National Institute of Standards and Technology finalized the first three post-quantum cryptography standards — FIPS 203, 204, and 205 — after an eight-year global evaluation process. The NSA’s CNSA 2.0 framework requires all new national security systems to implement quantum-safe algorithms starting in January 2027, with all custom and legacy applications migrated by 2030 and complete infrastructure migration by 2035. Canada has set federal deadlines requiring departments to submit PQC migration plans by April 2026, prioritize critical systems by 2031, and complete migration by 2035. The European Union is developing similar frameworks. On top of regulatory pressure sits the “harvest now, decrypt later” problem: adversaries are capturing encrypted data today in the expectation that quantum computing capability will decrypt it within a decade. In February 2026, Google publicly called on governments and industry to “prepare now” for quantum-era cybersecurity.

QSE has spent Q1 2026 building out the commercial, product, and channel infrastructure to serve that migration. On March 10, QSE disclosed that its operational footprint had expanded to 13 countries (up from four in November 2025), its value-added distributor network had grown to eleven partners, and the Company had secured memberships in CADSI (Canadian Association of Defence and Security Industries) and MISA (Municipal Information Systems Association) to support government procurement pathways. On March 12, QSE announced participation in a slate of major 2026 international cybersecurity conferences — including Cyber UK 2026 in Glasgow, GISEC Global in Dubai, and the Gartner Security & Risk Management Summit in Washington, D.C.

On March 18, QSE announced its first municipal government post-quantum security pilot, conducted through its MISA engagement — a reference deployment that can accelerate adoption across the broader public-sector market. And on March 31, 2026, QSE launched QPA v2, its enterprise post-quantum cryptographic migration platform, featuring a PQC Planning Wizard supporting governance design, budgeting, and migration strategy; AI-enhanced assessment modules; automated software, hardware, and cryptographic bill-of-materials (SBOM/CBOM/HBOM) analysis; and a centralized executive dashboard providing real-time visibility into quantum readiness. QPA v2 integrates with QSE’s broader stack — its qREK quantum-resilient key SDK, its QAuth identity and authentication platform, and its decentralized encrypted storage architecture — giving enterprise and government customers a full-stack option at the exact moment they need one.

Learn more about QSE at

USANewsGroup.com/qse-profile

Why This Group of Five, and Why Now

The five companies above do not belong to the same sector, and they are not comparable in any conventional apples-to-apples screen. What they share is something more specific and arguably more useful to a long-term investor: each one has stacked multiple catalysts into the first four months of 2026, and each of those catalysts is the kind that typically precedes — rather than follows — a broader re-reading of the story.

VWAV has closed financing, acquired IP, and is moving to take control of a publicly traded subsidiary. FJET has gone from its December 2025 NYSE American listing to the NYSE Opening Bell, expanded operations across two spaceports, added hypersonic, microgravity, and research-consortium partnerships, and filed its first annual report as a public company — all in the span of a few months. AVAI has moved its anti-aging program from JV formation to Master Cell Bank production and onto the podium at the field’s most prestigious conference. LVG has financed the bridge from permitted developer to producing miner. QSE has launched an enterprise platform into a regulatory deadline calendar that is, for once, already fully written down on paper.

Catalysts matter precisely because they are observable. Each of these five companies has provided investors with a verifiable sequence of events to monitor in 2026 — not a promise, not a thesis, but a running list. That is what “under the radar with catalysts ahead” actually looks like when it is working.

CONTACT: 

Market IQ Media Group
[email protected]
(604) 265-2873

Disclaimer

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. World Street Intelligence is owned and operated by Creative Digital Marketing Group. This distribution is being delivered by Market IQ Media Group, Inc. (“MIQ”) which owns and operates USA News Group, and Equity Insider. MIQ has been paid a fee for VisionWave Holdings, Inc. advertising and digital media from the company directly. MIQ has been paid a fee for Starfighters Space, Inc. digital media distribution services by Creative Digital Media Group (“CDMG”), which has been paid to produce and distribute digital media on the Company. MIQ has been paid a fee for Avaí Bio, Inc. advertising and digital media distribution from the Company directly. MIQ has been paid a fee for Lake Victoria Gold Ltd. advertising and digital media from the company directly. MIQ has previously been paid a fee for QSE – Quantum Secure Encryption Corp. advertising and digital media from the company directly, which has since expired, but own shares of the company. There may be 3rd parties who may have shares of all the companies mentioned herein, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ owns securities of VisionWave Holdings, Inc., Lake Victoria Gold, Quantum Secure Encryption, and Avai Bio which were purchased in the open market and/or through private placements. MIQ reserves the right to buy and sell, and will buy and sell shares of any of the company’s mentioned herein at any time hereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company’s mentioned herein, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by the corresponding companies or their agents; this is a paid advertisement, and we own shares of the mentioned companies that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. This article is being distributed for MIQ, who has been paid a fee for an advertising contract.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Sources

VisionWave Holdings, Inc.